Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francois Ghiringhelli

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
British Journal of Cancer|January 7, 2022
Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trialMarc Ychou, Michel Rivoire, Simon Thezenas, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|July 4, 2019
Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significanceSimon Pernot, Magali Terme, Nina Radosevic-Robin, et al.
The Oncologist|September 30, 2018
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent GlioblastomaAlba A Brandes, Miguel Gil-Gil, Frank Saran, et al.
European Journal of Cancer (Oxford, England : 1990)|July 5, 2022
Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancerValentin Derangère, Julie Lecuelle, Come Lepage, et al.
European Journal of Cancer (Oxford, England : 1990)|April 7, 2026
Corrigendum to "Combination of CDX2H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer" [In European Journal of Cancer, Volume 172, 2022, Pages 221-230, ISSN 0959-8049]Valentin Derangère, Julie Lecuelle, Come Lepage, et al.
BMC Cancer|November 10, 2023
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancerNicolas Roussot, Jean-David Fumet, Emeric Limagne, et al.
Ebiomedicine|January 11, 2020
Implementation and use of whole exome sequencing for metastatic solid cancerManon Réda, Corentin Richard, Aurelie Bertaut, et al.
Journal for Immunotherapy of Cancer|March 13, 2026
Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancerFrancois Ghiringhelli, Richard Kim, Teresa Macarulla, et al.
European Journal of Cancer (Oxford, England : 1990)|November 4, 2019
Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II studyThomas Walter, Come Lepage, Romain Coriat, et al.
JAMA Network Open|September 8, 2021
Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal CancerAlain R Thierry, Brice Pastor, Ekaterina Pisareva, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
British Journal of Cancer|January 7, 2022
Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trialMarc Ychou, Michel Rivoire, Simon Thezenas, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|July 4, 2019
Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significanceSimon Pernot, Magali Terme, Nina Radosevic-Robin, et al.
The Oncologist|September 30, 2018
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent GlioblastomaAlba A Brandes, Miguel Gil-Gil, Frank Saran, et al.
European Journal of Cancer (Oxford, England : 1990)|July 5, 2022
Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancerValentin Derangère, Julie Lecuelle, Come Lepage, et al.
European Journal of Cancer (Oxford, England : 1990)|April 7, 2026
Corrigendum to "Combination of CDX2H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer" [In European Journal of Cancer, Volume 172, 2022, Pages 221-230, ISSN 0959-8049]Valentin Derangère, Julie Lecuelle, Come Lepage, et al.
BMC Cancer|November 10, 2023
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancerNicolas Roussot, Jean-David Fumet, Emeric Limagne, et al.
Ebiomedicine|January 11, 2020
Implementation and use of whole exome sequencing for metastatic solid cancerManon Réda, Corentin Richard, Aurelie Bertaut, et al.
Journal for Immunotherapy of Cancer|March 13, 2026
Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancerFrancois Ghiringhelli, Richard Kim, Teresa Macarulla, et al.
European Journal of Cancer (Oxford, England : 1990)|November 4, 2019
Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II studyThomas Walter, Come Lepage, Romain Coriat, et al.
JAMA Network Open|September 8, 2021
Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal CancerAlain R Thierry, Brice Pastor, Ekaterina Pisareva, et al.
Pageof 10